EUVIMEDEUVIMED entdecken
Crossref

Therapeutic success of tofacitinib in granuloma annulare: A retrospective case series of 15 patients

Anubha Dev, Vinay Keshavamurthy, Debajyoti Chatterjee

Indian Journal of Dermatology, Venereology and Leprology · 2024

DOI: 10.25259/ijdvl_215_2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, 2024. Verfasst von Anubha Dev und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Granuloma Annulare, Pyrroles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Granuloma annulare (GA) is a necrobiotic granulomatous disorder that may sometimes be resistant to treatment, especially the generalised form. Tofacitinib has recently shown promise in the treatment of non-infective granulomatous dermatosis.

Objectives

In this study, we aimed to evaluate the response of generalised GA to oral tofacitinib.

Methods

This was a retrospective case series in patients of generalised GA who were treated with oral tofacitinib 5 mg twice a day in a tertiary care centre in north India. Baseline clinical details and histopathological findings were reviewed. Treatment response was noted in the form of clearance of lesions (complete or partial) along with the time taken to achieve the maximum response.

Results

A total of 15 patients of generalised GA were included in this study, amongst whom nine patients were resistant to conventional therapies whilst the remaining were treatment naïve. Complete clearance of lesions was noted in 11 patients at a mean treatment duration of 4.4 ± 2.1 months whereas clearance was partial in four, with a mean follow-up duration post- treatment in patients who had partial clearance, which is 7.3 ± 2.8 month, with a reduction in erythema and infiltration in those lesions. Adverse effects in the form of hyperlipidemia were observed in two patients.

Conclusion

Tofacitinib, a JAK-STAT inhibitor is beneficial in treating GA, especially in those with generalised and recalcitrant disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesPiperidinesGranuloma AnnularePyrrolesProtein Kinase InhibitorsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

JAK-STATgranuloma annularetofacitinib

Substanzen

tofacitinibPyrimidinesPiperidinesPyrrolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India.
  • Department of Pathology, PGIMER, Chandigarh, India.

Zitieren

APA

Dev, A., Keshavamurthy, V., & Chatterjee, D. (2024). Therapeutic success of tofacitinib in granuloma annulare: A retrospective case series of 15 patients. Indian Journal of Dermatology, Venereology and Leprology. https://doi.org/10.25259/ijdvl_215_2024

Vancouver

Dev A, Keshavamurthy V, Chatterjee D. Therapeutic success of tofacitinib in granuloma annulare: A retrospective case series of 15 patients. Indian Journal of Dermatology, Venereology and Leprology. 2024. doi:10.25259/ijdvl_215_2024

BibTeX
@article{Dev2024,
  author = {Dev, Anubha and Keshavamurthy, Vinay and Chatterjee, Debajyoti},
  title = {Therapeutic success of tofacitinib in granuloma annulare: A retrospective case series of 15 patients},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2024},
  doi = {10.25259/ijdvl_215_2024}
}
Kostenlos starten →